The rationale for treating allergic asthma with anti-IgE Source: Eur Respir Rev 2007; 16: 61-66 Year: 2007
Effect of treatment with anti-IgE antibody on airway inflammation in mild asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Effect of humanized monoclonal anti-IgE antibody, omalizumab, on allergen challenge-induced nasal response in subjects with allergic rhinitis and allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Source: Eur Respir J 2001; 18: 254-261 Year: 2001
Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases Source: Eur Respir Rev 2008; 17: 1-9 Year: 2008
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Staphylococcal Enterotoxins sensitization and response of Omalizumab in severe atopic and non atopic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
Specific immunotherapy in the management of allergic asthma Source: Annual Congress 2008 - PG2 - Asthma: natural history, risk factors and overall management Year: 2008
Allergen activates eosinophils of atopic bronchial asthma patients via IgE-mediated mechanism. Source: Virtual Congress 2020 – New insight into the pathogenesis of chronic lung diseases: asthma, COPD and others Year: 2020
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002
Immunotherapy prevents the development of asthma in subjects with allergic rhinitis Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001
Specific allergen immunotherapy of asthma combined with allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006
Omalizumab decreases IgE production in patients with severe allergic asthma Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012
Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005
How to evaluate a patient's response to anti-IgE Source: Eur Respir Rev 2007; 16: 78-84 Year: 2007
Anti-IgE treatment: An alternative for severe allergic occupational asthma Source: Annual Congress 2012 - Asthma and COPD at work: what are the effects of exposure and risk factors? Year: 2012
Treatment of co-morbid allergic asthma and perennial allergic rhinitis with the anti-IgE agent omalizumab Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003